Member Info for RayPointer

I guess what is does show is that generally the quickest way to market is via a trial in the US

"What we don’t know is when did Scancell put in the paperwork for MHRA or EMA. I’m hoping it was shortly after they got the FDA documents emailed at the end of December."

But don't the figures in the article refer to final approval of the therapy following a successful trial, rather than approval to go ahead with a clinical trial?

I think Phil made the point that producing trial results at frequent intervals could result in pharma losing interest.

That was why he was delaying the next release of Modi1 trial results. More patients, and a better indication of an emerging increase in PFS.

That's certainly good news for Scancell.

Of the Modi1 monotherapy cohorts, it was the one for Ovarian cancer that showed the most promise.

Unfortunately, at the time, there were no CPIs approved for treatment of Ovarian cancer, so it was decided to postpone further investigations until a CPI was approved.

Scancell could at some point now add a further cohort for Modi1 in combination with Keytruda.

Exactly TF.

There's a US government in place in which scientific evidence takes second place to certain persons' prejudices.

I thought that team ramp didn't read Porky's posts.

Moderna look to be in trouble in more ways than one.

I wonder what Kennedy thinks about DNA vaccines against cancer.

Https://faron.com/faron-pipeline/

It looks very much like Faron only have one product i.e. Bexmarilimab.

Having said that they are trialling it against multiple types of cancer mainly in combinations.

Bewmarilimab is another inhibitor and, as such, is aimed at removing the brakes on the immune system.

https://www.targetedonc.com/view/bexmarilimab-azacitidine-offers-efficacy-safety-in-high-risk-mds

The results seem impressive but maybe not enough to attract a pharma partner.

Chester, maybe I'm being too optimistic but:

a) the clinicians involved do not work for big pharma

b) Scancell is already seeking the equivalent of INDs in Europe and the UK. It wouldn't take that much to include Aus as well.

It seems very much like other admins are going the take the approved IND as almost a green light anyway.

c) How much of Scancell's involvement require face-to-face meetings? Could most of the communication be via video calls?

d) I would imagine most clinicians would be very keen to be involved in this trial; remember the Grand Challenge when several renowned clinicians were on Lindy's team

So what would make it more difficult or expensive to run a 4 country trial as opposed to a 2 country trial?

I can't see where there would be major difficulties or extra big expenses.

I'm willing to be persuaded otherwise.

Must be Liz the second then

Perhaps we should enter Scancell into the Antiques Roadshow

Not sure they have a biotech expect on that program

At least we can be thankful that Phil is trying to do a deal with pharma rather than government.

When it comes to science and technology, I've long thought that successive governments are clueless.

Well put Rats.

The other sentence I take pater to task on is:

"The combination of Mark’s grant winning experience and the UK’s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth."

Pater, pray tell us about Valirx's previous phases of growth.

Just looking at the first company on your list i.e.

Momentous Therapeutics Ltd (immunotherapy) - £2m grant

I notice that they have a world-renowned scientist on their BOD. This may go some way to explaining the grant they received.

That plus the cutting edge research they are undertaking on the immune system.

Here he is:

https://www.meduniwien.ac.at/web/en/ueber-uns/news/2025/news-in-june-2025/christoph-huber-receives-german-cancer-aid-award/

Exactly, why worry about day to day antics of the MMs when Scancell are in the position they are in.

There are far more important things going on.

There were 4 research agreements for glymabs/avidimab but not necessarily 4 separate parties.

Of these 4 research agreements, we know that:

a) 1st the geographical location is not mentioned

b) 2nd with a Chinese company

c) 3rd with a US company

d) 4th with a European company

I'm guessing 1st and 4th were both Genmab. That leaves 2 other parties showing early interest. Who knows if they are still interested, but Genmab still progressing their 2 chosen mAbs towards the clinic must have a positive effect.

https://www.lse.co.uk/rns/SCLP/first-collaboration-agreement-for-avidimab-4k85nlprsdq9zn8.html

https://www.lse.co.uk/rns/SCLP/second-agreement-signed-for-avidimab-platform-cdfpz3ot8voo0rq.html

https://www.lse.co.uk/rns/SCLP/third-agreement-signed-for-antibody-platform-jrztb6gl8ahy0hr.html

https://www.lse.co.uk/rns/SCLP/scancell-progresses-its-new-anti-glycan-mab-kde9mwc49rra8mh.html

Few hours, few days or few months 😂

0 questions back from the FDA after IND submission!

ISCIB3+, iSCIB4+

Now under study